OnKure Therapeutics, Inc. (OKUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.35 Million) by net assets ($172.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OKUR market cap overview for the company's overall valuation and market capitalisation.
OnKure Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how OnKure Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
OnKure Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore OnKure Therapeutics, Inc. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DMS Propertindo Tbk PT
JK:KOTA
|
-0.003x |
|
Haesung Industrial Co. Ltd
KQ:034810
|
0.020x |
|
Technos S.A
SA:TECN3
|
0.012x |
|
Torimbia Socimi S.A.
MC:YTRM
|
0.191x |
|
The Pinkfong Company
KQ:403850
|
0.012x |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
-0.019x |
|
Bellevue Group AG
SW:BBN
|
0.150x |
|
WMG Holdings Bhd
KLSE:6378
|
-0.090x |
Annual Cash Flow Conversion Efficiency for OnKure Therapeutics, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of OnKure Therapeutics, Inc. from 2020 to 2025. View OnKure Therapeutics, Inc. (OKUR) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.18 Million | $-51.83 Million | -0.922x | -87.37% |
| 2024-12-31 | $103.83 Million | $-51.12 Million | -0.492x | -245.14% |
| 2023-12-31 | $-101.84 Million | $-34.55 Million | 0.339x | -31.51% |
| 2022-12-31 | $-54.42 Million | $-26.95 Million | 0.495x | +291.96% |
| 2021-12-31 | $147.21 Million | $-37.98 Million | -0.258x | -158.62% |
| 2020-12-31 | $-42.12 Million | $-18.54 Million | 0.440x | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more